Skip to content

MDMA: all studies

Page 276 of 347: studies 2,751 to 2,760 of 3,461, newest first. Back to the MDMA overview

Research

Novel harm reduction measures at music festivals in Australia: Pilot implementation of the Emerging Drugs Network of Australia-Victoria toxicosurveillance methodology.

Drug and Alcohol Review November 1, 2024 Rebekka Syrjanen, Martin Dutch, Shaun L. Greene et al. 3 citations

Harm reduction strategies at music festivals seek to create a safer environment for patrons. The Emerging Drugs Network of Australia-Victoria (EDNAV) project is a state-wide toxicosurveillance network that derives drug intelligence from a sample of patients presenting to hospital with illicit drug-related toxicity. This publication describes the preliminary outcomes of conducting...

DOI: 10.1111/dar.13922 (opens in new tab) Full text (opens in new tab) Nps Illicit drugs Music festivals Toxicosurveillance +4

“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin

Journal of Psychedelic Studies October 29, 2024 Pamela Kryskow, Paul Stamets, Joseph T. la Torre et al. 4 citations

Abstract Interest in psychedelic research in the West is surging, however, clinical trials have almost exclusively studied synthetic compounds such as MDMA, ketamine, DMT, LSD, ibogaine, and psilocybin. To date, few clinical trials have utilized whole mushroom/plant material like Psilocybe mushrooms, Iboga, or Ayahuasca. Individuals participating in the Roots To Thrive Psilocybin-Assisted...

The Antecedents of the Experience of Light in Dreams

Religions October 25, 2024 Gregory S. Sparrow, Ryan Hurd

The experience of inner light and ecstasy is widely accepted as a universal mystical experience, regardless of cultural or religious context. While one can read first-hand accounts in the historical record, the direct experience of light remains elusive for most people. This study analyzes a series of dream-based experiences of light provided by a single subject. In our analysis of 19 dreams,...

Expert recommendations for Germany’s integration of psychedelic-assisted therapy

BMC Medical Education October 24, 2024 Susanne Birnkammer, Olga Chernoloz, Sergio Pérez Rosal et al. 10 citations

As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psychedelic-assisted therapy (PAT) and supporting psychedelic drug research. This paper evaluates the necessary frameworks for implementing PAT in Germany, emphasizing the nation's potential leadership role within the European Union. With Australia having...

Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada

PLoS One October 24, 2024 Kyurim Kim, Abban Yusuf, Abhimanyu Sud et al. 1 citation

Psychedelics, including ketamine, 3,4-Methyl enedioxy methamphetamine (MDMA), and psilocybin, have gained attention for their potential therapeutic role in mental health treatment. While recreational use is prohibited in Canada, medicinal exemptions can be granted. There are several psychedelic clinics in Ontario, Canada, promoting the use of psychedelics for a variety of medical indications....

DOI: 10.1371/journal.pone.0309911 (opens in new tab) Psychedelic therapy Mental health treatment Clinical research Medical ethics +1

Implementation of a community-based LC-UV drug checking service: promising preliminary findings on feasibility and validity.

Harm Reduction Journal October 18, 2024 Nicolas Fabresse, Eurydice Papias, Alma Heckenroth et al. 3 citations

The increasing diversity of psychoactive substances on the unregulated drug market poses significant health, psychological, and social risks to people who use drugs (PWUD). To address these risks, various harm reduction (HR) policies have been implemented, including drug checking services (DCS). Many analytical methods are used for DCS. While qualitative methods (e.g., thin layer...

DOI: 10.1186/s12954-024-01098-4 (opens in new tab) Full text (opens in new tab) Cross-validation Drug checking Harm reduction Lc-hrms +4

Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science

Translational Behavioral Medicine October 17, 2024 Danielle R Adams, Heidi L Allen, Ginger E. Nicol et al. 7 citations

Abstract Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the potential to produce rapid therapeutic effects when paired with psychotherapy. Randomized clinical trials of psychedelic-assisted psychotherapy (PAT) have shown promising results for post-traumatic stress disorder (PTSD), depression, and substance use...

A survey investigating United States federal grant submissions proposing to investigate therapeutic applications of psychedelics

medRxiv October 13, 2024 Brian S. Barnett preprint

Abstract This study surveyed researchers to assess the contents and funding success of federal grant applications for research into therapeutic applications of psychedelics in the United States. The author emailed an anonymous survey to the corresponding authors of the 50 most-cited articles on psychedelics published after 2000 and disseminated it via Twitter. Ten researchers responded,...

DOI: 10.1101/2024.10.12.24315367 (opens in new tab) Full text (opens in new tab) Survey research Library science Applied psychology

Snapshot of 5-HT 2A receptor activation in the mouse brain via IP 1 detection.

bioRxiv : the preprint server for biology October 12, 2024 Mario de la Fuente Revenga, Javier González-Maeso preprint

The distinct subjective effects that define psychedelics such as LSD, psilocybin or DOI as drug class are causally linked to activation of the serotonin 2A receptor (5-HT 2A R). However, some aspects of 5-HT 2A R pharmacology remain elusive, such as what molecular drivers differentiate psychedelic from non-psychedelic 5-HT 2A R agonists. We developed an ex vivo platform to obtain snapshots of...

Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine—A Systematic Review and Meta-Analysis

Psychoactives October 4, 2024 Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar 2 citations

Background: There is ongoing research into the potential use of psychedelics and 3,4-methylenedioxy-methamphetamine (MDMA) as alternatives to commonly used medications for treating major depressive and anxiety disorders. Aims: We aimed to assess the efficacy of psychedelics and MDMA in managing depressive and anxiety symptoms and evaluate their safety profiles. Methods: We searched five...

DOI: 10.3390/psychoactives3040029 (opens in new tab) Meta-analysis Antidepressant Methylenedioxy Methamphetamine +1